On 9 and 10 January, members of the work packages for the EPAD (European Prevention of Alzheimer’s Dementia) and AMYPAD (AMYloid imaging to Prevent Alzheimer’s Disease) projects met in Cambridge, UK to discuss ongoing work to provide ethics guidance for the two projects.
Richard Milne presented the preliminary findings from a related study, which explored attitudes towards the communication of various kinds of risk status linked to Alzheimer’s dementia.
Members of the group discussed plans for work related to the two projects and emphasised the need to progress with the setting up of the participant panel to ensure that research participants have the opportunity to contribute towards improving the experience of research participants involved in these studies.
The EPAD project has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.
The AMYPAD project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. The Joint Undertaking receives support from the European Union’s Horizon2020 research and innovation programme and EFPIA.